Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

Nature Medicine

Volumn 6, Issue 1, 2000, Pages 76-81

  Sharkey, Mark E ^a   Teo, Ian ^b   Greenough, Thomas ^a   Sharova, Natalia ^a   Luzuriaga, Katherine ^a   Sullivan, John L ^a   Bucy, R Pat ^c   Kostrikis, Leondios G ^d   Haase, Ashley ^e   Veryard, Claire ^b   Davaro, Raul E ^f   Cheeseman, Sarah H ^f   Daly, Jennifer S ^f   Bova, Carol ^f   Ellison III, Richard T ^f   Mady, Brian ^f   Lai, Kwan Kew ^f   Moyle, Graeme ^g   Nelson, Mark ^g   Gazzard, Brian ^g   Shaunak, Sunil ^b   Stevenson, Mario ^a   more..

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c University of Alabama at Birmingham   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f University of Massachusetts   (United States)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; LYMPHOCYTES; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033966504     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/71569     Document Type: Article

References (21)

1. Perelson, A.S., Neumann, A.U., Markowtiz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
2. Gulick, R.M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
3. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1227 (1997).
4. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
5. Zhang, H. et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339, 1803-1809 (1998).
6. Chun, T.W. et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95, 8869-8873 (1998).
7. Stevenson, M. et al. Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64, 2421-2425 (1990).
8. Zhang, L. et al. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J. Virol. 73, 855-860 (1999).
9. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
10. Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
11. Brown, P.O., Bowerman, B., Varmus, H.E. & Bishop, J.M. Correct integration of retroviral DNA in vitro. Cell 49, 347-356 (1987).
12. Bukrinsky, M.I., Stanwick, T.L., Dempsey, M.P. & Stevenson, M. Quiescent T lymphocytes as an inducible virus reservoir in HlV-1 infection. Science 254, 423-427 (1991).
13. Zack, J.A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-222 (1990).
14. Stevenson, M., Stanwick, T.L., Dempsey, M.P. & Lamonica, C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560 (1990).
15. Sonza, S. et al. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70, 3863-3869 (1996).
16. Livingstone, W.J., Moore, M., Innes, D., Bell, J.E. & Simmonds, P. Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet 348, 649-654 (1996).
17. Chun, T.W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387, 183-188 (1997).
18. Spina, C.A., Prince, H.E. & Richman, D.D. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99, 1774-1785 (1997).
19. Riley, J.L. et al. Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implications for transmission and pathogenesis. J. Virol. 72, 8273-8280 (1998).
20. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
21. Cowan, N.J., Dobner, P.R., Fuchs, E.V. & Cleveland, D.W. Expression of human alpha-tubulin genes: interspecies conservation of 3′ untranslated regions. Mol. Cell. Biol. 3, 1738-1745 (1983).